RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF CEBRANOPADOL FOR THE TREATMENT OF ACUTE PAIN AFTER ABDOMINOPLASTY (ASRA-SPRING 2025) - Apr 27, 2025 - Abstract #6666; Pres time: May 1, 2025; 05:15 PM - 06:00 PM; Location: Gatlin C; "Ondansetron 4mg was administered for prophylaxis of nausea and vomiting with the possibility of a supplementary dose. Rescue medications included IV morphine for the first 24 hours following study drug administration followed by oral oxycodone thereafter...Cebranopadol, a novel analgesic with a unique dual mechanism of action as a nociceptin/orphanin FQ peptide (NOP) receptor and mu-opioid receptor agonist, demonstrates a more promising balance of efficacy and safety in treating moderate to severe acute pain. This study highlights cebranopadol's potential to become a valuable new therapy for acute pain management."
Clinical • P3 data • Addiction (Opioid and Alcohol) • Aesthetic Medicine • Anesthesia • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Pain • Psychiatry
|
|
Neil Singla; Harold Minkowitz; Ben Vaughn; Joseph Grieco; Marc Lesnick; James Hackworth
|